Skip to main content

Table 4 Changes in serum fat metabolic markers from baseline to 8 weeks in the Placebo and in LI85008F supplemented group

From: Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study

Parameter Study Period Placebo (x ± SE) P valuea LI85008F (x ± SE) P valuea (P value)b
Cholesterol (mM/L) Baseline 5.33 ± 0.23 0.1176 5.58 ± 0.25 0.6479 -
8 week 5.64 ± 0.22 5.48 ± 0.24
Change −0.32 ± 0.19 - 0.09 ± 0.20 - 0.149
HDL-Cholesterol (mM/L) Baseline 2.18 ± 0.05 0.5812 2.12 ± 0.08 0.2192 -
8 week 2.14 ± 0.05 2.23 ± 0.07
Change 0.04 ± 0.07 - −0.11 ± 0.09 - 0.11
LDL-Cholesterol (mM/L) Baseline 9.03 ± 0.28 0.0925 9.21 ± 0.29 0.0005 -
8 week 8.41 ± 0.28 7.67 ± 0.28
Change 0.62 ± 0.35 - 1.53 ± 0.37 - 0.0834
Triglycerides (mM/L) Baseline 0.33 ± 0.01 0.8148 0.32 ± 0.02 0.0389 -
8 week 0.33 ± 0.01 0.29 ± 0.01
Change 0.00 ± 0.01 - 0.03 ± 0.02 - 0.063
Glucose (mM/L) Baseline 6.98 ± 0.61 0.8726 6.88 ± 0.35 0.0033 -
8 week 6.91 ± 0.57 5.93 ± 0.27
Change 0.07 ± 0.41 - 0.94 ± 0.28 - 0.0669
  1. a Difference within the group (baseline vs. final evaluation) using paired t-test.
  2. b Difference between changes (derived from baseline minus final evaluation) in placebo and LI85008F group using unpaired t-test.